AMRX — Amneal Pharmaceuticals Inc. stock price and chart

AMRX

$19.84+2.48%

as of close, Oct 20, 2026

☾ AH $19.84 +2.48%

Amneal Pharmaceuticals Inc.Stock · HealthcareRussell 2000 · 0.09% of IWMNasdaq Composite · 0.01% of ONEQRussell 3000 · 0.004% of IWVUS Stock Market · 0.004% of VTI

PeersMRNALLYMDTUNHJNJTMO

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

Available history since May 11, 2018

VolumeEEEEEEEEEEEE

20182020202220242026

2.04.06.08.010.012.014.016.018.020.022.0020.0M40.0M$19.84

2026-10-20

Price$19.84

MA20$18.19

MA50$14.93

Vol5.2M

What would $1,000 invested in AMRX be worth today? →

AMRX returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $19.84
YTD price return: +57.46%
YTD total return: +57.46%
Next earnings: Nov 3, 2026 · Before open
Market cap: 6.3B2018-09 6.6B2026-10 6.3B-4.3% over the window
Enterprise value: 8.9B
Shares outstanding: 319.4M2018-06 298.4M2026-06 319.4M+7.0% over the window
52W low: $9.92
52W high: $21.18
From 52W high: -6.30%
From 52W low: +100.00%
52W range: 88%

Volume

Rel volume: 1.56×
30D volume: 3.3M
30D $ vol: 64.8M

Fundamentals

Sales (ttm): 3.1B2016-12 1B2026-06 3.1B+206.2% over the window
Sales/share: $9.762017-12 $3.462026-06 $9.76+181.9% over the window
EPS (ttm): $0.482017-12 $0.002026-06 $0.48
FCF (ttm): 127.8M2016-12 -7.7M2026-06 127.8M-1761.1% over the window
FCF/share: $0.402017-12 $0.472026-06 $0.40-14.3% over the window
Book value/share: $0.102017-12 $0.002026-06 $0.10
Net margin: 5.05%2016-12 0.0%2026-06 5.0%
ROE: 476.51%2018-12 -3.9%2026-06 476.5%-12281.9% over the window
ROA: 4.17%2017-12 12.6%2026-06 4.2%-67.0% over the window
Debt / equity: 77.65×2018-06 5.342026-06 77.65+1353.8% over the window
Current ratio: 2.202017-12 2.602026-06 2.20-15.2% over the window

Growth (CAGR, ttm) · 10Y

Sales: +9.28%2025-06-30 → 2026-06-302.9B → 3.1B (+9.3% total)+10.48%2023-06-30 → 2026-06-302.3B → 3.1B (+34.8% total)+8.67%2021-06-30 → 2026-06-302.1B → 3.1B (+51.5% total)+12.51%2016-12-31 → 2026-06-301B → 3.1B (+206.2% total)
Net income: +4574.89%2025-06-30 → 2026-06-303.4M → 157.4M (+4562.6% total)n/a+61.64%2021-06-30 → 2026-06-3014.3M → 157.4M (+1002.9% total)n/a
FCF: -54.85%2025-06-30 → 2026-06-30283M → 127.8M (-54.8% total)-4.42%2023-06-30 → 2026-06-30146.4M → 127.8M (-12.7% total)-7.31%2021-06-30 → 2026-06-30186.8M → 127.8M (-31.6% total)n/a
Shares: +1.68%2025-06-30 → 2026-06-30314.1M → 319.4M (+1.7% total)-19.50%2023-06-30 → 2026-06-30612.3M → 319.4M (-47.8% total)+16.01%2021-06-30 → 2026-06-30152M → 319.4M (+110.1% total)n/a

Per-share growth (CAGR, ttm) · 10Y

EPS: +4417.51%2025-06-30 → 2026-06-30$0.01 → $0.48 (+4405.7% total)n/a+38.29%2021-06-30 → 2026-06-30$0.10 → $0.48 (+405.7% total)n/a
Sales/share: +7.48%2025-06-30 → 2026-06-30$9.08 → $9.76 (+7.5% total)+37.24%2023-06-30 → 2026-06-30$3.78 → $9.76 (+158.6% total)-6.33%2021-06-30 → 2026-06-30$13.54 → $9.76 (-27.9% total)n/a
FCF/share: -55.60%2025-06-30 → 2026-06-30$0.90 → $0.40 (-55.6% total)+18.74%2023-06-30 → 2026-06-30$0.24 → $0.40 (+67.4% total)-20.10%2021-06-30 → 2026-06-30$1.23 → $0.40 (-67.4% total)n/a
Book value/share: n/a-41.61%2023-06-30 → 2026-06-30$0.52 → $0.10 (-80.1% total)-46.12%2021-06-30 → 2026-06-30$2.28 → $0.10 (-95.5% total)n/a
Dividend/share: -51.51%2018-06-30 → 2019-03-31$0.88 → $0.51 (-41.9% total)n/an/an/a
Price: +93.84%2025-10-20 → 2026-10-20$10.24 → $19.84 (+93.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+78.79%2023-10-20 → 2026-10-20$3.47 → $19.84 (+471.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+28.25%2021-10-20 → 2026-10-20$5.72 → $19.84 (+246.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +93.84%2025-10-20 → 2026-10-20$10.24 → $19.84 (+93.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+78.79%2023-10-20 → 2026-10-20$3.47 → $19.84 (+471.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+28.25%2021-10-20 → 2026-10-20$5.72 → $19.84 (+246.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 41.3×2018-09 39.112026-10 40.26+2.9% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 14.0×2018-09 164.482026-10 13.96-91.5% over the window
Fwd P/E: 16.1×
P/S (ttm)Market cap ÷ TTM revenue.: 2.0×2018-09 5.352026-10 2.03-62.0% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 191.9×2018-09 13.392026-10 191.86+1332.6% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 49.6×2018-09 -88.542026-10 49.56-156.0% over the window
EV/EBITDA (fy): 14.4×
EV/Sales (ttm): 2.9×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 2.02%2018-06 -1.1%2026-06 2.3%-304.8% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 319.4M ÷ 314.1M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -1.68%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-1.68%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($2.5B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -1.68%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($6.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2018-06 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($6.3B). Same caveat as the cash buyback yield.: 0.00%2018-06 4.0%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/E: 37th
P/OI: 75th
P/S: 89th
P/B: 99th
P/FCF: 96th

Bar = where today’s multiple sits in AMRX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-20#

+2.48%

+1.38%

+6.04%

+13.37%

YTD

+57.46%

+93.75%

+246.85%

Financial statements

Open full AMRX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+11.34%	+3.49%
JNJ	Johnson & Johnson	-3.94%	+2.19%
ABBV	AbbVie Inc.	+9.52%	+2.26%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+11.24%	+3.04%
MRK	Merck & Co. Inc.	+0.97%	+3.25%
NVS	Novartis AG	+9.45%	+2.29%
TMO	Thermo Fisher Scientific Inc.	+5.51%	+1.18%
AMGN	Amgen Inc.	+13.82%	+3.29%

AMRX — Amneal Pharmaceuticals Inc. price, chart and key statistics